^
    Back
    Association details:
    Biomarker:FGFR1-PLAG1 fusion
    Cancer:Head and Neck Cancer
    Drug:Lytgobi (futibatinib) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Cancer Discov
    Title:

    Futibatinib, an irreversible FGFR1–4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study

    Published date:
    09/22/2021
    Excerpt:
    Among the 170 patients who received futibatinib 20 mg QD, 10.6% experienced PRs, and 38.2% experienced SD...PRs were observed in a patient with head and neck cancer harboring an FGFR1-PLAG1 fusion (DOR, 5.6 months) and another patient with an FGFR2 p.Y375C mutation (DOR, 10.3 months) whose primary tumor was unknown.
    DOI:
    10.1158/2159-8290.CD-21-0697
    Trial ID:
    FOENIX-CCA2